Objective: This study aimed to compare the clinical and economic outcomes between excisional debridement with a local xylocaine block (LAD) and excisional debridement under general anesthesia (GAD). Material and Methods: This retrospective medical record review was designed to review records of excisional debridement in necrotizing fasciitis (NF) at Sisaket Hospital from January 1, 2017, to December 31, 2019. Outcome measures were clinical outcomes at the preoperative time (baseline data, door-to-operating room), peri-operative time (operating time, blood loss, number of reoperations), postoperative time (mortality rate, length of stay, pain score, opioid drug use), types of NF, and direct costs of treatment by the provider’s perspective. Descriptive statistics, chi-square and Mann-Whitney U test were used. Results: The results of 245 patients showed that LAD was superior to GAD in terms of door-to-operating room time, lower operating time and blood loss, shorter length of hospital stay and lower cost of treatment. Moreover, the LAD showed a lower postoperative pain score, and less opioid drug use when compared to GAD. There were no significant differences in mortality rate, sites of infection and types of NF. Conclusion: LAD showed better clinical outcomes and lower cost of treatment when compared to GAD in the treatment of NF. Nevertheless, excisional debridement under a LAD could be a choice for small wounds at the lower extremities in hospitals with limited resources, and insufficient numbers of anesthesiologists.
{"title":"A Comparative Study between Surgical Techniques by Local Excisional debridement with a Xylocaine Block and Excisional Debridement under General Anesthesia, in Necrotizing Fasciitis","authors":"Mongkhon Phattharathiwanon","doi":"10.31584/jhsmr.2023927","DOIUrl":"https://doi.org/10.31584/jhsmr.2023927","url":null,"abstract":"Objective: This study aimed to compare the clinical and economic outcomes between excisional debridement with a local xylocaine block (LAD) and excisional debridement under general anesthesia (GAD). Material and Methods: This retrospective medical record review was designed to review records of excisional debridement in necrotizing fasciitis (NF) at Sisaket Hospital from January 1, 2017, to December 31, 2019. Outcome measures were clinical outcomes at the preoperative time (baseline data, door-to-operating room), peri-operative time (operating time, blood loss, number of reoperations), postoperative time (mortality rate, length of stay, pain score, opioid drug use), types of NF, and direct costs of treatment by the provider’s perspective. Descriptive statistics, chi-square and Mann-Whitney U test were used. Results: The results of 245 patients showed that LAD was superior to GAD in terms of door-to-operating room time, lower operating time and blood loss, shorter length of hospital stay and lower cost of treatment. Moreover, the LAD showed a lower postoperative pain score, and less opioid drug use when compared to GAD. There were no significant differences in mortality rate, sites of infection and types of NF. Conclusion: LAD showed better clinical outcomes and lower cost of treatment when compared to GAD in the treatment of NF. Nevertheless, excisional debridement under a LAD could be a choice for small wounds at the lower extremities in hospitals with limited resources, and insufficient numbers of anesthesiologists.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48638931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: This study aimed to assess clinical, humanistic and economic outcomes of telepharmacy in asthma patients. Material and Methods: A quasi-experimental research design, with one-group pretest-posttest, was conducted to study telepharmacy. This real-time pharmaceutical care using communication technology was conducted in 29 asthma patients, over 12 weeks. Clinical outcomes were evaluated; including, asthma control, drug-related problems, adherence to use of inhaled corticosteroids (ICS), ICS-side effects, emergency room visits and hospitalizations due to acute exacerbation. Patient satisfaction was used to assess humanistic outcomes, and cost-saving was used to assess economic outcomes. Results: Clinical outcomes showed statistically significant improvement in the number of well-controlled patients; increasing from 34.48% to 89.66% (p-value<0.01). ICS adherence improved from the mean percentage of number of times patients forgot to use ICS; which decreased from 5.86±18.67 to 0.21±0.74 (p-value<0.01). The mean number of drug-related problems decreased from 1.45±0.91 to 0.21±0.41 (p-value<0.01), and the mean number of ICS-side effects decreased from 0.66±0.72 to 0.14±0.44 (p-value<0.01). A total of 51.72 % of patients also required additional advice on inhaler techniques by a pharmacist. The mean number of emergency room visits and hospitalizations, due to acute exacerbation, decreased to zero by the end of the study. Humanistic outcomes revealed that patient satisfaction was at the ‘very satisfactory’ level (4.82±0.27 out of 5.00), and economic outcomes found that patients could save 49.99±34.90% compared to usual care. Conclusion: This study shows that patients receiving telepharmacy have better outcomes in ICS adherence and asthma control, can prevent future risks (acute exacerbation, ICS-side effects), save costs and were very satisfied with telepharmacy overall.
{"title":"Outcomes of Telepharmacy on Asthma Control at Ratchaburi Hospital","authors":"Wiwat Thavornwattanayong, Patchawalai Nuallaong","doi":"10.31584/jhsmr.2023928","DOIUrl":"https://doi.org/10.31584/jhsmr.2023928","url":null,"abstract":"Objective: This study aimed to assess clinical, humanistic and economic outcomes of telepharmacy in asthma patients. Material and Methods: A quasi-experimental research design, with one-group pretest-posttest, was conducted to study telepharmacy. This real-time pharmaceutical care using communication technology was conducted in 29 asthma patients, over 12 weeks. Clinical outcomes were evaluated; including, asthma control, drug-related problems, adherence to use of inhaled corticosteroids (ICS), ICS-side effects, emergency room visits and hospitalizations due to acute exacerbation. Patient satisfaction was used to assess humanistic outcomes, and cost-saving was used to assess economic outcomes. Results: Clinical outcomes showed statistically significant improvement in the number of well-controlled patients; increasing from 34.48% to 89.66% (p-value<0.01). ICS adherence improved from the mean percentage of number of times patients forgot to use ICS; which decreased from 5.86±18.67 to 0.21±0.74 (p-value<0.01). The mean number of drug-related problems decreased from 1.45±0.91 to 0.21±0.41 (p-value<0.01), and the mean number of ICS-side effects decreased from 0.66±0.72 to 0.14±0.44 (p-value<0.01). A total of 51.72 % of patients also required additional advice on inhaler techniques by a pharmacist. The mean number of emergency room visits and hospitalizations, due to acute exacerbation, decreased to zero by the end of the study. Humanistic outcomes revealed that patient satisfaction was at the ‘very satisfactory’ level (4.82±0.27 out of 5.00), and economic outcomes found that patients could save 49.99±34.90% compared to usual care. Conclusion: This study shows that patients receiving telepharmacy have better outcomes in ICS adherence and asthma control, can prevent future risks (acute exacerbation, ICS-side effects), save costs and were very satisfied with telepharmacy overall.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44123355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A patent is the main design of Intellectual Property Rights employed in the pharmaceutical industry. Claims of patents in India are imposed under the Patents Act of 1970. The goal of patent authorization is to inspire and progress in the industry and associated modern technologies. Intellectual property rights can help grow the economy due to their industrial applicability in regard to businesses within the country as well as exports. The Indian pharmaceutical industry, is a distinctly uneven one, is influenced by others and there were difficulties in regards to intellectual property rights in the context of the world trade organization.This review illustrates a brief outline of patent law in India due to the significance of Trade-Related Aspects of Intellectual Property Rights (TRIPS) contracts and the benefits of patentability as well as different types of pharmaceutical patents are described accordingly. Other appropriate necessities linked with patenting of pharmaceuticals like, pre and post-trade related aspects of Intellectual Property Rights, compulsory licensing etc. are also explained. The objective of this paper is to study the patent act of the pharmaceutical industry and several patents granted in India in the pharmaceutical industry, aiming to provide information in the context of pharmaceutical patenting.
{"title":"A Review on the Indian Patent System and Its Implication on the Pharmaceutical Industry","authors":"D. Dash, Riya Vaiswade, Gayatri K. Gupta","doi":"10.31584/jhsmr.2023926","DOIUrl":"https://doi.org/10.31584/jhsmr.2023926","url":null,"abstract":"A patent is the main design of Intellectual Property Rights employed in the pharmaceutical industry. Claims of patents in India are imposed under the Patents Act of 1970. The goal of patent authorization is to inspire and progress in the industry and associated modern technologies. Intellectual property rights can help grow the economy due to their industrial applicability in regard to businesses within the country as well as exports. The Indian pharmaceutical industry, is a distinctly uneven one, is influenced by others and there were difficulties in regards to intellectual property rights in the context of the world trade organization.This review illustrates a brief outline of patent law in India due to the significance of Trade-Related Aspects of Intellectual Property Rights (TRIPS) contracts and the benefits of patentability as well as different types of pharmaceutical patents are described accordingly. Other appropriate necessities linked with patenting of pharmaceuticals like, pre and post-trade related aspects of Intellectual Property Rights, compulsory licensing etc. are also explained. The objective of this paper is to study the patent act of the pharmaceutical industry and several patents granted in India in the pharmaceutical industry, aiming to provide information in the context of pharmaceutical patenting.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45176763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nattawat Siurai, Prin Twinprai, D. Theerakulpisut, J. Chindaprasirt, Y. Raruenrom
Objective: To examine factors associated with bone scintigraphy (BS) positivity in cases with cholangiocarcinoma (CCA) to help assess appropriate utilization of BS in CCA patients. Material and Methods: This cross-sectional study enrolled CCA patients who underwent BS for detection of bone metastasis between January 2012 and July 2020. The BS images were reviewed by two nuclear medicine physicians to assess BS positivity. Factors including tumor location, T stage, regional lymph node metastasis, other distant metastases, and serum carbohydrate antigen 19-9 (CA19-9) were evaluated. Associations between covariates and positive BS were analyzed using bivariate and multiple logistic regressions. Results: Among 158 CCA patients, 70 (44.3%), 84 (53.2%), and 4 (2.5%) had positive, negative, and equivocal BS, respectively. Of all 70 positive cases, 50 cases (71.4%) had multiple metastatic lesions. The spine was the most common metastatic site (n=55, 78.6%). After exclusion of equivocal cases, 154 were included in the regression models. In bivariate logistic regression, the factors associated with BS positivity were intrahepatic tumor location (OR=2.18, p-value=0.039) and other distant metastasis (OR=2.08, p-value=0.028). Further analysis using multiple logistic regression showed only other distant metastasis was associated with positive BS (OR=2.66, p-value=0.008). Conclusion: There was a significant association between other distant metastasis and BS positivity in CCA patients. This factor should be considered as a clinical indication for requesting BS in this group of patients.
{"title":"Factors Associated with Bone Scintigraphy Positivity in Cholangiocarcinoma","authors":"Nattawat Siurai, Prin Twinprai, D. Theerakulpisut, J. Chindaprasirt, Y. Raruenrom","doi":"10.31584/jhsmr.2023925","DOIUrl":"https://doi.org/10.31584/jhsmr.2023925","url":null,"abstract":"Objective: To examine factors associated with bone scintigraphy (BS) positivity in cases with cholangiocarcinoma (CCA) to help assess appropriate utilization of BS in CCA patients. Material and Methods: This cross-sectional study enrolled CCA patients who underwent BS for detection of bone metastasis between January 2012 and July 2020. The BS images were reviewed by two nuclear medicine physicians to assess BS positivity. Factors including tumor location, T stage, regional lymph node metastasis, other distant metastases, and serum carbohydrate antigen 19-9 (CA19-9) were evaluated. Associations between covariates and positive BS were analyzed using bivariate and multiple logistic regressions. Results: Among 158 CCA patients, 70 (44.3%), 84 (53.2%), and 4 (2.5%) had positive, negative, and equivocal BS, respectively. Of all 70 positive cases, 50 cases (71.4%) had multiple metastatic lesions. The spine was the most common metastatic site (n=55, 78.6%). After exclusion of equivocal cases, 154 were included in the regression models. In bivariate logistic regression, the factors associated with BS positivity were intrahepatic tumor location (OR=2.18, p-value=0.039) and other distant metastasis (OR=2.08, p-value=0.028). Further analysis using multiple logistic regression showed only other distant metastasis was associated with positive BS (OR=2.66, p-value=0.008). Conclusion: There was a significant association between other distant metastasis and BS positivity in CCA patients. This factor should be considered as a clinical indication for requesting BS in this group of patients.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43117553","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Saranyoo Suwansa-Ard, Peerasak Chortrakarnkij, V. Vathanophas
Objective: To identify the incidence of recurrent otitis media in cleft palate patients after palatoplasty and myringotomy 14 ";">with ventilation tube (VT) insertion in addition to identifying risk factors of recurrent otitis media with effusion (OME). Material and Methods: This retrospective cohort study was conducted from; January 2002 – December 2014. A total of 120 non- syndromic cleft palate patients were included and analyzed for risk factors contributing to recurrent otitis 14 ";">media with effusion. Results: 14 ";">In total, 77.5% of the VT slipped off at 10 months after their initial operation. The incidence of recurrent OME was 54.2% at 7 months after VT slipped off. Significant risk factors that were associated to recurrent OME included: complete cleft palate, two-stage palatoplasty and VT slip-off (p-value<0.05). Conclusion: 14 ";">The incidence of recurrence OME was 54.2%, and risk factors for recurrence OME are VT slipped off, complete cleft palate and two-stage palatoplasty.
{"title":"Long Term Study of Otitis Media with Effusion after Palatoplasty and Myringotomy with Ventilation Tube Insertion","authors":"Saranyoo Suwansa-Ard, Peerasak Chortrakarnkij, V. Vathanophas","doi":"10.31584/jhsmr.2023924","DOIUrl":"https://doi.org/10.31584/jhsmr.2023924","url":null,"abstract":"Objective: To identify the incidence of recurrent otitis media in cleft palate patients after palatoplasty and myringotomy 14 \";\">with ventilation tube (VT) insertion in addition to identifying risk factors of recurrent otitis media with effusion (OME). Material and Methods: This retrospective cohort study was conducted from; January 2002 – December 2014. A total of 120 non- syndromic cleft palate patients were included and analyzed for risk factors contributing to recurrent otitis 14 \";\">media with effusion. Results: 14 \";\">In total, 77.5% of the VT slipped off at 10 months after their initial operation. The incidence of recurrent OME was 54.2% at 7 months after VT slipped off. Significant risk factors that were associated to recurrent OME included: complete cleft palate, two-stage palatoplasty and VT slip-off (p-value<0.05). Conclusion: 14 \";\">The incidence of recurrence OME was 54.2%, and risk factors for recurrence OME are VT slipped off, complete cleft palate and two-stage palatoplasty.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46316967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K. Khuancharee, C. Tanunyutthawongse, Chawin Suwanchatchai, S. Wannaiampikul
Objective: This study aimed to investigate whether the risk of gout was associated with the ABCG2 rs2231142 variant and how this was affected by metabolic parameters. Material and Methods: The subjects were selected from the genetic variations of urate transporter genes in hyperuricemia and gout in the Thai population (GUHGTH) study. Overall, 96 participants aged 30-60 years were included in the study. Adjusted odds ratio (AORs) of gout was analyzed using multiple logistic regression models and the effects of combinations of ABCG2 rs2231142 variants and metabolic parameters on gout were explored. Results: The TG and TT genotypes of ABCG2 rs2231142 and hyperglycemia were significantly associated with gout risk. The risk of gout was significantly increased by the combined association of ABCG2 rs2231142 and metabolic parameters obesity and hyperglycemia for the TG and TT genotypes compared to the GG genotype (wild-type genotype). Conclusion: In conclusion, the ABCG2 rs2231142 variant was found to be a genetic risk factor for gout in Thai men. Obesity and hyperglycemia combined with the ABCG2 rs2231142 risk allele contributed to an increase in the risk of gout. Further case-control studies with larger sample sizes should be performed to confirm the combinations of the ABCG2 rs2231142 variant, obesity, and hyperglycemia on the risk of gout.
{"title":"Associations and Combinations of Metabolic Parameters and ABCG2 rs2231142 Variant in Thai Men with Gout","authors":"K. Khuancharee, C. Tanunyutthawongse, Chawin Suwanchatchai, S. Wannaiampikul","doi":"10.31584/jhsmr.2023923","DOIUrl":"https://doi.org/10.31584/jhsmr.2023923","url":null,"abstract":"Objective: This study aimed to investigate whether the risk of gout was associated with the ABCG2 rs2231142 variant and how this was affected by metabolic parameters. Material and Methods: The subjects were selected from the genetic variations of urate transporter genes in hyperuricemia and gout in the Thai population (GUHGTH) study. Overall, 96 participants aged 30-60 years were included in the study. Adjusted odds ratio (AORs) of gout was analyzed using multiple logistic regression models and the effects of combinations of ABCG2 rs2231142 variants and metabolic parameters on gout were explored. Results: The TG and TT genotypes of ABCG2 rs2231142 and hyperglycemia were significantly associated with gout risk. The risk of gout was significantly increased by the combined association of ABCG2 rs2231142 and metabolic parameters obesity and hyperglycemia for the TG and TT genotypes compared to the GG genotype (wild-type genotype). Conclusion: In conclusion, the ABCG2 rs2231142 variant was found to be a genetic risk factor for gout in Thai men. Obesity and hyperglycemia combined with the ABCG2 rs2231142 risk allele contributed to an increase in the risk of gout. Further case-control studies with larger sample sizes should be performed to confirm the combinations of the ABCG2 rs2231142 variant, obesity, and hyperglycemia on the risk of gout.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48497601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: To identify the magnitude of catastrophic health expenditure (CHE) and medical impoverishment across three payment schemes and compare the within-scheme financial disparity. Material and Methods: A cross-sectional analysis of CHE and medical impoverishment among lung cancer patients was conducted at a university hospital in Thailand. A total of 367 lung cancer patients drawn from three payment schemes were included. The clinical data were collected from the hospital’s Electronic Medical Records, while the socioeconomic data, including cost details, were collected via an interview-based questionnaire from November 2020 to June 2022. Economic analyses were performed using concentration curves and logistic regression modeling. Results: There were 38%, 21% and 27% impoverished patients belonging to the Universal Coverage Scheme (UCS), Social Security Scheme (SSS) and Civil Servant Medical Benefit Scheme (CSMBS), respectively, and approximately further 30% in each scheme became impoverished owing to medical-related expenses. Socioeconomic disparities in CHE; concentration index; CI=-0.36 UCS, -0.59 CSMBS and -0.47 UCS, and medical impoverishment; CI=0.16 UCS, -0.15 CSMBS and 0.10 UCS, were evident in all schemes. These inequities were more pronounced among CSMBS patients. Moreover, if not impoverished already, the probability of medical impoverishment in all payment schemes peaked in the middle quintile and declined thereafter. Conclusion: Across all payment schemes, CHE and medical impoverishment occurred at rates of around 60% and 30%, respectively, among lung cancer patients in Thailand. The gradient of CHE probability was more prominent among CSMBS patients.
{"title":"Catastrophic and Socioeconomic Disparities Across Different Payment Schemes in Lung Cancer Treatment: A Cross-Sectional Single-Centre Analysis from Thailand","authors":"Sarayut Lucien Geater, P. Thongsuksai","doi":"10.31584/jhsmr.2023921","DOIUrl":"https://doi.org/10.31584/jhsmr.2023921","url":null,"abstract":"Objective: To identify the magnitude of catastrophic health expenditure (CHE) and medical impoverishment across three payment schemes and compare the within-scheme financial disparity. Material and Methods: A cross-sectional analysis of CHE and medical impoverishment among lung cancer patients was conducted at a university hospital in Thailand. A total of 367 lung cancer patients drawn from three payment schemes were included. The clinical data were collected from the hospital’s Electronic Medical Records, while the socioeconomic data, including cost details, were collected via an interview-based questionnaire from November 2020 to June 2022. Economic analyses were performed using concentration curves and logistic regression modeling. Results: There were 38%, 21% and 27% impoverished patients belonging to the Universal Coverage Scheme (UCS), Social Security Scheme (SSS) and Civil Servant Medical Benefit Scheme (CSMBS), respectively, and approximately further 30% in each scheme became impoverished owing to medical-related expenses. Socioeconomic disparities in CHE; concentration index; CI=-0.36 UCS, -0.59 CSMBS and -0.47 UCS, and medical impoverishment; CI=0.16 UCS, -0.15 CSMBS and 0.10 UCS, were evident in all schemes. These inequities were more pronounced among CSMBS patients. Moreover, if not impoverished already, the probability of medical impoverishment in all payment schemes peaked in the middle quintile and declined thereafter. Conclusion: Across all payment schemes, CHE and medical impoverishment occurred at rates of around 60% and 30%, respectively, among lung cancer patients in Thailand. The gradient of CHE probability was more prominent among CSMBS patients.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48232961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atipath Nualla-Ong, T. Wongwananuruk, S. Angsuwathana, K. Techatraisak, M. Rattanachaiyanont, P. Tanmahasamut, S. Indhavivadhana, P. Chantrapanichkul
Objective: To measure the difference in fasting blood glucose (FBG) among Thai women with polycystic ovary syndrome (PCOS), having received either oral combined contraceptive pills (OCP) or cyclic progestin, during 3 years of treatment. Materials and Methods: The data were collected by a retrospective chart review of women with PCOS, who had been treated at Siriraj Hospital before June 2019, backward to the year 2000. The patients were divided into two groups, according to their different treatments, namely: an OCP group and a cyclic progestin group. There were 44 cases in each group, and both groups had received complete hormonal treatment over 3 years. Results: The patients’ baseline characteristics showed a significantly lower body mass index (BMI) and waist circumference (WC) in the OCP group than in the cyclic progestin treatment group. After the 3-year period of treatment, the FBG differences in the OCP group and cyclic progestin treatment group were 3.4±8.4 and 3.6±8.5 mg/dL, respectively; which revealed no statistical significance. Additionally, the difference in the WC and metabolic profile between the studied groups after 3 years of treatment also revealed no significance. However, BMI presented a significant difference between the two hormonal regimens after 3 years of treatment (p-value=0.007), with higher differences in the OCP treatment group. Conclusion: There was no statistically significant difference in FBG between the beginning and at the third year of treatment found in both regimens of hormonal treatment in Thai PCOS women.
{"title":"Association between Glucose Metabolism and Oral Combined Contraceptive Pills or Cyclic Progestin in Thai Women with Polycystic Ovary Syndrome: A 3-year Observational Study","authors":"Atipath Nualla-Ong, T. Wongwananuruk, S. Angsuwathana, K. Techatraisak, M. Rattanachaiyanont, P. Tanmahasamut, S. Indhavivadhana, P. Chantrapanichkul","doi":"10.31584/jhsmr.2023920","DOIUrl":"https://doi.org/10.31584/jhsmr.2023920","url":null,"abstract":"Objective: To measure the difference in fasting blood glucose (FBG) among Thai women with polycystic ovary syndrome (PCOS), having received either oral combined contraceptive pills (OCP) or cyclic progestin, during 3 years of treatment. Materials and Methods: The data were collected by a retrospective chart review of women with PCOS, who had been treated at Siriraj Hospital before June 2019, backward to the year 2000. The patients were divided into two groups, according to their different treatments, namely: an OCP group and a cyclic progestin group. There were 44 cases in each group, and both groups had received complete hormonal treatment over 3 years. Results: The patients’ baseline characteristics showed a significantly lower body mass index (BMI) and waist circumference (WC) in the OCP group than in the cyclic progestin treatment group. After the 3-year period of treatment, the FBG differences in the OCP group and cyclic progestin treatment group were 3.4±8.4 and 3.6±8.5 mg/dL, respectively; which revealed no statistical significance. Additionally, the difference in the WC and metabolic profile between the studied groups after 3 years of treatment also revealed no significance. However, BMI presented a significant difference between the two hormonal regimens after 3 years of treatment (p-value=0.007), with higher differences in the OCP treatment group. Conclusion: There was no statistically significant difference in FBG between the beginning and at the third year of treatment found in both regimens of hormonal treatment in Thai PCOS women. ","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42420786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Objective: The literature presents a variety of Human Immunodeficiency Virus (HIV) stigma scales focused on the self, social aspects, and health worker issues. Scarcity was noted on instruments developed to assess HIV-related stigma in health facilities. This paper aims to present the rigors in designing and developing a psychometrically reliable and valid scale to assess HIV-related stigma in health facilities. Material and Methods: A sequential exploratory mixed method design was utilized following a Qual-Quan approach. Key informant interviews were used to gather first-hand experience of stigma in health facilities among key populations and persons living with HIV. Thematic analysis was utilized to analyze the narratives and pick out statements for item generation in the scale. The quantitative phase was done through item and scale validation, exploratory factor analysis, and reliability assessment using Cronbach’s alpha. Results: Two factors were extracted which were categorized as (1) Facility Structure and Protocol, and (2) Health Personnel. The scale has very high internal consistency as per Cronbach’s alpha value of 0.91, suggestive of its high reliability in measuring HIV-related stigma in health facilities. Conclusion: The scale may be utilized by health facilities to assess and evaluate their health service provision, particularly on their client’s perception of health facility-related stigma.
{"title":"Development and Psychometric Evaluation of the HIV-Related Stigma in Health Facilities (HIV-SHF) Scale","authors":"Janet Alexis A. De los Santos","doi":"10.31584/jhsmr.2023922","DOIUrl":"https://doi.org/10.31584/jhsmr.2023922","url":null,"abstract":"Objective: The literature presents a variety of Human Immunodeficiency Virus (HIV) stigma scales focused on the self, social aspects, and health worker issues. Scarcity was noted on instruments developed to assess HIV-related stigma in health facilities. This paper aims to present the rigors in designing and developing a psychometrically reliable and valid scale to assess HIV-related stigma in health facilities. Material and Methods: A sequential exploratory mixed method design was utilized following a Qual-Quan approach. Key informant interviews were used to gather first-hand experience of stigma in health facilities among key populations and persons living with HIV. Thematic analysis was utilized to analyze the narratives and pick out statements for item generation in the scale. The quantitative phase was done through item and scale validation, exploratory factor analysis, and reliability assessment using Cronbach’s alpha. Results: Two factors were extracted which were categorized as (1) Facility Structure and Protocol, and (2) Health Personnel. The scale has very high internal consistency as per Cronbach’s alpha value of 0.91, suggestive of its high reliability in measuring HIV-related stigma in health facilities. Conclusion: The scale may be utilized by health facilities to assess and evaluate their health service provision, particularly on their client’s perception of health facility-related stigma.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44776483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natjira Tassaneesuwan, Chayanee Thammarat, P. Khongkow
Objective: Cannabidiol (CBD), a phytochemical active compound from the Cannabis sativa L., has become a popular ingredient in many industries, especially skincare products. However, the scientific evidence supporting its potential skin benefits and safety concerns are still unclear. Therefore, the aim of this study was to investigate the short-term and long-term cytotoxic effects of CBD and its potential melanin-promoting effect on skin cells in order to deeply evaluate the safety of CBD for use in cosmetics. Material and Methods: HaCaT keratinocytes and B16F10 melanoma cell lines were cultured and investigated in regard to the cytotoxicity of cannabidiol in various concentrations (0-10 μg/ml) in the short term and long term by sulforhodamine B (SRB) assay and clonogenic assay, respectively. Next, the cellular melanin production was measured by melanin content assay. The expression of the related genes was accessed by qPCR. Results: The short-term and long-term cytotoxicity studies revealed that CBD at a low concentration was not toxic to skin cells. In addition, CBD could induce melanogenesis in melanocytes by increasing melanin content and upregulating tyrosinase expression. Also, CBD provoked cell proliferation and enhanced vascular endothelial growth factor (VEGF) mRNA expression in keratinocytes. Conclusion: Our study demonstrated that CBD at a low concentration (0.6 μg/ml) is safe for the skin cells in vitro and should thus also be safe if applied to skin. Additionally, CBD could significantly enhance melanogenesis and cell proliferation, which confirms its potential as a cosmeceutical product.
{"title":"Safety and Potential Effects of Cannabidiol on Skin Cells","authors":"Natjira Tassaneesuwan, Chayanee Thammarat, P. Khongkow","doi":"10.31584/jhsmr.2023919","DOIUrl":"https://doi.org/10.31584/jhsmr.2023919","url":null,"abstract":"Objective: Cannabidiol (CBD), a phytochemical active compound from the Cannabis sativa L., has become a popular ingredient in many industries, especially skincare products. However, the scientific evidence supporting its potential skin benefits and safety concerns are still unclear. Therefore, the aim of this study was to investigate the short-term and long-term cytotoxic effects of CBD and its potential melanin-promoting effect on skin cells in order to deeply evaluate the safety of CBD for use in cosmetics. Material and Methods: HaCaT keratinocytes and B16F10 melanoma cell lines were cultured and investigated in regard to the cytotoxicity of cannabidiol in various concentrations (0-10 μg/ml) in the short term and long term by sulforhodamine B (SRB) assay and clonogenic assay, respectively. Next, the cellular melanin production was measured by melanin content assay. The expression of the related genes was accessed by qPCR. Results: The short-term and long-term cytotoxicity studies revealed that CBD at a low concentration was not toxic to skin cells. In addition, CBD could induce melanogenesis in melanocytes by increasing melanin content and upregulating tyrosinase expression. Also, CBD provoked cell proliferation and enhanced vascular endothelial growth factor (VEGF) mRNA expression in keratinocytes. Conclusion: Our study demonstrated that CBD at a low concentration (0.6 μg/ml) is safe for the skin cells in vitro and should thus also be safe if applied to skin. Additionally, CBD could significantly enhance melanogenesis and cell proliferation, which confirms its potential as a cosmeceutical product.","PeriodicalId":36211,"journal":{"name":"Journal of Health Science and Medical Research","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45390225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：